Multiple Myeloma and Related Diseases
Pathophysiology
A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
Kyle RA, Therneau TM, Rajkumar SV, et al.
N Engl J Med. 2002;346:564-569.
Description: Largest analysis of long-term prognosis of monoclonal gammopathy of uncertain significance (MGUS).
PubMed citation number: 11856795
Multiple myeloma: evolving genetic events and host interactions.
Kuehl WM, Bergsagel PL.
Nat Rev Cancer. 2002;2:175-187.
Description: A review of the molecular aspects of multiple myeloma.
PubMed citation number: 11990854
Advances in biology of multiple myeloma: clinical applications.
Hideshima T, Bergsagel PL, Kuehl WM, Anderson K.
Blood. 2004;104:607-618.
Description: Description of the molecular pathways involved in the pathogenesis of monoclonal gammopathy of undetermined significance and multiple myeloma.
PubMed citation number: 15090448
Diagnosis
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorder: report of the International Myeloma Working Group.
International Myeloma Working Group.
Br J Haematol. 2003;121:749-757.
Description: Review of the classification of monoclonal gammopathies, including monoclonal gammopathy of undetermined significance, smouldering myeloma, non-secretory myeloma, solitary plasmacytomas, and symptomatic myeloma.
PubMed citation number: 12780789
International staging system for multiple myeloma.
Greipp P, San Miguel J, Durie B, et al.
J Clin Oncol. 2005;23:3412.
Description: International Myeloma Foundation describes a new international staging system of multiple myeloma. The system is validated using data from patients of all ages, with or without transplantation, from North America, Europe, and Asia.
PubMed citation number: 15809451
Treatment
Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
Dimopoulos MA, Moulopoulos LA, Maniatis A, Alexanian R.
Blood. 2000;96:2037-2044.
Description: A review of management of solitary plasmacytoma.
PubMed citation number: 10979944
Treatment of multiple myeloma.
Bartogie B, Shaughnessy J, Tricot G, et al.
Blood. 2004;103:20-32.
Description: A review article of the management of multiple myeloma.
PubMed citation number: 12969978
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.
Myeloma Trialists’ Collaborative Group.
J Clin Oncol. 1998;16:3832-3842.
Description: Extensive review of the use of chemotherapy for multiple myeloma.
PubMed citation number: 9850028
Single versus double autologous stem-cell transplantation for multiple myeloma.
Attal M, Harousseau JL, Facon T, et al: Intergroupe Francophone du Myelome.
N Engl J Med. 2003;349:2495-2502.
Description: Role of single and double transplants in multiple myeloma.
PubMed citation number: 14695409
Antitumor activity of thalidomide in refractory multiple myeloma.
Singhal S, Mehta J, Desikan R, et al.
N Engl J Med. 1999;341:1565-1571.
Description: The use of thalidomide in relapsed multiple myeloma.
PubMed citation number: 10564685
A phase II study of bortezomib in relapsed, refractory myeloma.
Richardson P, Bartogie B, Berenson J, et al.
N Engl J Med. 2003;348:2609-2617.
Description: The use of a novel agent, Velcade, in relapsed multiple myeloma.
PubMed citation number: 12826635
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
Berenson JR, Hillner BE, Kyle RA, et al.
J Clin Oncol. 2002;20:3719-3736.
Description: The role of bisphosphonates in bony disease in multiple myeloma.
PubMed citation number: 12202673
Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma.
Dammaco F, Castoldi G, Rodjer S.
Br J Haem. 2001;113:172-179.
Description: The role of erythropoietin alfa in the multiple myeloma and its impact of transfusion requirements and quality of life.
PubMed citation number: 11328297
Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma.
Jagannath S, Durie BG, Wof J, et al.
Br J Haem. 2005;129:776.
Description: Phase 2 study using bortezomib with and without dexamethasone for primary treatment of multiple myeloma, resulting in high response rates.
PubMed citation number: 1593004
Superiority of thalidomide and dexamethasone over Vincristin-Doxorubicin-Dexamethasone (VAD) in preparation for autologous stem cell transplantation in multiple myeloma.
Cavo M, Zamagni E, Tosi P, et al.
Blood. 2005;106:35-39.
Description: A retrospective analysis of patients with previously untreated multiple myeloma who were given vincristine, adriamycin, and dexamethasone versus thalidomide and dexamethasone as first-line treatment.
PubMed citation number: 15761019
Review
POEMS syndrome: definitions and long-term outcome.
Dispenzieri A, Kyle RA, Lacy MQ, et al.
Blood. 2003;101:2496-2506.
Description: A review of a series of 99 patients with POEMS syndrome.
PubMed citation number: 12456500
Multiple myeloma.
Kyle RA, Rajkumar SV.
N Eng J Med. 2004;351:1860-1872.
Description: A recent review of treatment options for multiple myeloma, including drug therapy, transplantation, and treatment of myeloma complications.
PubMed citation number: 15509819